AAPL   324.91 (+0.48%)
MSFT   185.06 (+0.08%)
FB   230.58 (-0.92%)
GOOGL   1,438.76 (-0.25%)
NVDA   351.94 (-0.30%)
CGC   16.66 (+3.22%)
BABA   217.91 (+1.67%)
MU   49.24 (+5.17%)
GE   7.32 (+3.83%)
TSLA   883.68 (+0.24%)
T   31.59 (+1.94%)
GILD   74.06 (+1.09%)
DIS   122.15 (+2.86%)
NFLX   423.27 (-0.95%)
BAC   26.04 (+4.83%)
BA   171.66 (+11.97%)
AAPL   324.91 (+0.48%)
MSFT   185.06 (+0.08%)
FB   230.58 (-0.92%)
GOOGL   1,438.76 (-0.25%)
NVDA   351.94 (-0.30%)
CGC   16.66 (+3.22%)
BABA   217.91 (+1.67%)
MU   49.24 (+5.17%)
GE   7.32 (+3.83%)
TSLA   883.68 (+0.24%)
T   31.59 (+1.94%)
GILD   74.06 (+1.09%)
DIS   122.15 (+2.86%)
NFLX   423.27 (-0.95%)
BAC   26.04 (+4.83%)
BA   171.66 (+11.97%)
AAPL   324.91 (+0.48%)
MSFT   185.06 (+0.08%)
FB   230.58 (-0.92%)
GOOGL   1,438.76 (-0.25%)
NVDA   351.94 (-0.30%)
CGC   16.66 (+3.22%)
BABA   217.91 (+1.67%)
MU   49.24 (+5.17%)
GE   7.32 (+3.83%)
TSLA   883.68 (+0.24%)
T   31.59 (+1.94%)
GILD   74.06 (+1.09%)
DIS   122.15 (+2.86%)
NFLX   423.27 (-0.95%)
BAC   26.04 (+4.83%)
BA   171.66 (+11.97%)
AAPL   324.91 (+0.48%)
MSFT   185.06 (+0.08%)
FB   230.58 (-0.92%)
GOOGL   1,438.76 (-0.25%)
NVDA   351.94 (-0.30%)
CGC   16.66 (+3.22%)
BABA   217.91 (+1.67%)
MU   49.24 (+5.17%)
GE   7.32 (+3.83%)
TSLA   883.68 (+0.24%)
T   31.59 (+1.94%)
GILD   74.06 (+1.09%)
DIS   122.15 (+2.86%)
NFLX   423.27 (-0.95%)
BAC   26.04 (+4.83%)
BA   171.66 (+11.97%)
Log in

OTCMKTS:ENZNEnzon Pharmaceuticals Stock Price, Forecast & News

$0.17
0.00 (0.00 %)
(As of 06/3/2020 02:56 PM ET)
Add
Compare
Today's Range
$0.17
Now: $0.17
$0.18
50-Day Range
$0.15
MA: $0.17
$0.18
52-Week Range
$0.14
Now: $0.17
$0.31
Volume12,444 shs
Average Volume18,469 shs
Market Capitalization$7.53 million
P/E Ratio1.25
Dividend YieldN/A
Beta0.16
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolOTCMKTS:ENZN
Previous SymbolNASDAQ:ENZN
CUSIP29390410
Phone732-980-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$210,000.00
Book Value$0.14 per share

Profitability

Net Income$-980,000.00
Net Margins-326.92%

Miscellaneous

EmployeesN/A
Market Cap$7.53 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive ENZN News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZN and its competitors with MarketBeat's FREE daily newsletter.

Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions

How has Enzon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Enzon Pharmaceuticals' stock was trading at $0.1693 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ENZN stock has increased by 0.5% and is now trading at $0.1702. View which stocks have been most impacted by Coronavirus.

When is Enzon Pharmaceuticals' next earnings date?

Enzon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Enzon Pharmaceuticals.

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) released its earnings results on Thursday, April, 30th. The biotechnology company reported ($0.01) earnings per share for the quarter. Enzon Pharmaceuticals had a negative net margin of 326.92% and a negative return on equity of 11.28%. View Enzon Pharmaceuticals' earnings history.

Has Enzon Pharmaceuticals been receiving favorable news coverage?

Media headlines about ENZN stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Enzon Pharmaceuticals earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutEnzon Pharmaceuticals.

Who are some of Enzon Pharmaceuticals' key competitors?

What other stocks do shareholders of Enzon Pharmaceuticals own?

Who are Enzon Pharmaceuticals' key executives?

Enzon Pharmaceuticals' management team includes the following people:
  • Mr. Andrew Rackear, CEO & Sec. (Age 65)
  • Mr. Richard L. Feinstein, VP of Fin. & CFO (Age 76)

What is Enzon Pharmaceuticals' stock symbol?

Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."

How do I buy shares of Enzon Pharmaceuticals?

Shares of ENZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Enzon Pharmaceuticals' stock price today?

One share of ENZN stock can currently be purchased for approximately $0.17.

How big of a company is Enzon Pharmaceuticals?

Enzon Pharmaceuticals has a market capitalization of $7.53 million and generates $210,000.00 in revenue each year.

What is Enzon Pharmaceuticals' official website?

The official website for Enzon Pharmaceuticals is www.enzon.com.

How can I contact Enzon Pharmaceuticals?

Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.